secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2026-05-18T20:58:36+00:00
Accession:  0001437749-26-017637
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed reports Q1 2026 net loss of $8.0M; cash runway only into Sept 2026
---------------------------------------------------------------------------

- Net loss $8.0M vs $4.9M YoY; no grant revenue vs $1.9M prior year.
- Cash, cash equivalents and marketable securities $12.9M as of March 31, 2026, down from $20.9M at Dec 31, 2025.
- Cash runway expected to fund operations into September 2026.
- Plans to initiate Phase 3 DLB trial in H2 2026, subject to financing.
- Presented new MRI and biomarker data at AAN 2026 and AD/PD 2026 supporting neflamapimod.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774926017637/0001437749-26-017637-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774926017637/crvo20260518_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-017637

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer